Astrazeneca ADR Stock
Price
Target price
€70.00
€70.00
4.480%
3.0
4.480%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Astrazeneca ADR Stock
Astrazeneca ADR dominated the market today, gaining €3.00 (4.480%).
So far the community has only identified positive things for Astrazeneca ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | 4.480% | 3.876% | 8.943% | -2.899% | 8.943% | 54.734% | - |
| GSK plc ADR | 0.000% | 2.688% | -2.551% | 15.060% | 13.690% | -2.051% | -14.422% |
| Bayer AG ADR | - | 2.326% | 3.125% | -55.705% | -23.256% | -51.111% | -56.579% |
| Roche Holding AG ADR | -1.810% | 1.098% | -1.615% | -20.480% | -11.858% | -18.669% | - |
News
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q4 2023 Earnings CallFeb 08, 2024, 6:45 a.m. ET
Andy Barnett
Source Fool.com
AstraZeneca: Rebound in 2024 with double-digit earnings growth
U.K.-based AstraZeneca PLC (NASDAQ: AZN) is up 8.95% in the past month as investors grow optimistic about the company's improved earnings outlook for 2024. Not only are sales of cancer and
